ANI Pharmaceuticals' stock surged 5.35% during the pre-market session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.

The company reported adjusted earnings per share of $2.05, beating the consensus estimate of $1.30 by 56.49%. Quarterly sales reached $237.462 million, surpassing the estimate of $207.565 million by 14.40%. This represents a year-over-year increase of over 20% for both metrics.

Adding to the positive sentiment, ANI Pharmaceuticals raised its full-year 2026 financial outlook. The company now forecasts adjusted EPS between $9.19 and $9.69, compared to the previous Ibes estimate of $9.07, and expects revenue in the range of $1,080 to $1,140 million, above the estimated $1,050 million. Furthermore, the Board of Directors authorized a new $100 million share repurchase program.